Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inmed Pharmaceuticals Inc (NQ: INM )

1.260 -0.010 (-0.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 64,768
Open 1.270
Bid (Size) 1.260 (1)
Ask (Size) 1.330 (24)
Prev. Close 1.270
Today's Range 1.210 - 1.300
52wk Range 0.9213 - 19.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Participate in Virtual Investor Events Next Week
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Participate in Virtual Investor Events Next Week
Via CannabisNewsWire

Performance

YTD
-42.99%
-42.99%
1 Month
+7.69%
+7.69%
3 Month
-5.97%
-5.97%
6 Month
-51.91%
-51.91%
1 Year
-93.45%
-93.45%

More News

Read More
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO Featured in Upcoming Water Tower Research Fireside Chat
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO Featured in Upcoming Water Tower Research Fireside Chat
Via Investor Brand Network
InMed Pharmaceuticals Stock Trading Higher On Q3 Sales Growth Of 234%, Here Is What You Need To Know
Via Benzinga
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 2023 Financial Results, Provides Business Update
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 2023 Financial Results, Provides Business Update
Via CannabisNewsWire
InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Concludes Enrollment for Phase 2 Trial Studying INM-755 Cannabinol Cream
Via Investor Brand Network
InMed Pharmaceuticals: Pushing Pharma Forward With Rare Cannabinoids
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Why Bed Bath & Beyond Shares Are Trading Lower By Around 24%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Despite Global Economic Pressures, InMed Pharma's Accomplishments In 2022 Could Be A Catalyst For Further Growth In 2023
Via Benzinga
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Peer-Reviewed Study Results Published
Via Investor Brand Network
Rare Cannabinoids Could Help Treat Atopic Dermatitis, Psoriasis, Pruritus And Acne: New Study
Via Benzinga
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO to Present at Two March Investor Events
Via Investor Brand Network
Life Sciences Virtual Investor Forum Agenda Announced for March 9th
From Virtual Investor Conferences
Via GlobeNewswire
TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q2 2023 Financial, Corporate Report
Via Investor Brand Network
InMed Pharmaceuticals Q2 FY23 Revenue Grows 77% YoY, What About Net Loss?
Via Benzinga
InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update
From InMed Pharmaceuticals Inc.
Via GlobeNewswire
InMed Submits Form 12b-25
From InMed Pharmaceuticals Inc.
Via GlobeNewswire
Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
This Company's Rare Cannabinoids May Hold Promise In The Treatment Of Neurodegenerative Diseases Like Alzheimer's
Via Benzinga
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Key Milestones, 2023 Business Outlook
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Key Milestones, 2023 Business Outlook
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.